Receptor News and Research

RSS

Positive results from NanoString's second clinical study of PAM50-based breast cancer assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced positive results from the second clinical validation study of its in vitro diagnostic breast cancer assay based on the PAM50 gene expression signature.

From NanoString Technologies 7 Dec 2012

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Whole genome sequencing has revealed previously unreported mutations in metastatic triple-negative breast cancer (TNBC), according to a study published by the journal Molecular Cancer Therapeutics.

6 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Researchers unlock mechanisms of how the body converts dietary carbohydrates into fat

A gene that helps the body convert that big plate of holiday cookies you just polished off into fat could provide a new target for potential treatments for fatty liver disease, diabetes and obesity.

6 Dec 2012

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

6 Dec 2012

Western University research could lead to better treatments for PTSD and drug addiction

New research from Western University could lead to better treatments for Post-Traumatic Stress Disorder (PTSD) and drug addiction by effectively blocking memories. The research performed by Nicole Lauzon, a PhD candidate in the laboratory of Steven Laviolette at Western's Schulich School of Medicine & Dentistry has revealed a common mechanism in a region of the brain called the pre-limbic cortex, can control the recall of memories linked to both aversive, traumatic experiences associated with PTSD and rewarding memories linked to drug addiction.

6 Dec 2012

‘Pain as reward’ raises tolerance threshold

An individual’s ability to tolerate pain is influenced by their preconceptions and beliefs about the meaning of the pain, Italian researchers have shown.

5 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Researchers investigate GPER receptor as possible new drug target for breast cancer

Five-year breast cancer survival rates have improved dramatically over the past 50 years, but tumors can recur up to ten or more years after they are detected. When tumors recur, they are even more difficult to treat.

5 Dec 2012

Rethinking therapy decisions in autoimmune encephalopathy

Researchers say that diagnosis and management of encephalopathies may need to be rethought, as many patients who test negative for the relevant antibody still benefit from immunotherapy.

4 Dec 2012

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.

3 Dec 2012

Vitamin D receptor polymorphism may protect against osteoporosis

A polymorphism in the vitamin D receptor gene significantly influences risk for osteoporosis, suggest results from a meta-analysis of 26 studies.

3 Dec 2012

Tissue damage, disease severity in C. diff. infection associated with disruption of PPARγ pathway

Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.

1 Dec 2012

Study of hospital-acquired infection yields potential therapeutic target

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Fn14 gene plays a role in growth and spread of non-small cell lung cancer tumors

Lung cancer researchers at St. Joseph's Hospital and Medical Center in Phoenix, Ariz., in collaboration with researchers at the Translational Genomics Research Institute and other institutions, have identified a gene that plays a role in the growth and spread of non-small cell lung cancer tumors, opening the door for potential new treatment options.

30 Nov 2012

Modified vitamin D receptor may reduce risk of osteoporosis

Osteoporosis, or reduced bone mineral density that can increase the risk of fractures, may affect as many as 30% of women and 12% of men worldwide. One risk factor for osteoporosis is vitamin D deficiency.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

LP-211 compound shows promise against Fragile X syndrome

A potential new therapeutic strategy for treating Fragile X syndrome is detailed in a new report appearing in the current issue of Biological Psychiatry, from researchers led by Dr. Lucia Ciranna at University of Catania in Italy.

29 Nov 2012

Study identifies metabolic factors related to bread's beneficial effects on cardiovascular health

According to a study, daily bread consumption, especially wholemeal bread, can prevent cardiovascular disease. The study has been led by the professor Rafael Llorach, Ramon y Cajal researcher from the Department of Nutrition and Bromatology at the Faculty of Pharmacy and from the Food and Nutrition Torribera campus of the University of Barcelona.

29 Nov 2012

Receptor News and Research

Positive results from NanoString's second clinical study of PAM50-based breast cancer assay

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Researchers unlock mechanisms of how the body converts dietary carbohydrates into fat

Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Western University research could lead to better treatments for PTSD and drug addiction

‘Pain as reward’ raises tolerance threshold

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Researchers investigate GPER receptor as possible new drug target for breast cancer

Rethinking therapy decisions in autoimmune encephalopathy

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Vitamin D receptor polymorphism may protect against osteoporosis

Tissue damage, disease severity in C. diff. infection associated with disruption of PPARγ pathway

Study of hospital-acquired infection yields potential therapeutic target

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Fn14 gene plays a role in growth and spread of non-small cell lung cancer tumors

Modified vitamin D receptor may reduce risk of osteoporosis

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

LP-211 compound shows promise against Fragile X syndrome

Study identifies metabolic factors related to bread's beneficial effects on cardiovascular health

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News